Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Walter

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Biorxiv : the Preprint Server for Biology|March 16, 2022
Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibodyMichael S Piepenbrink, Jun-Gyu Park, Ashlesha Desphande, et al.
Clinical and Vaccine Immunology : CVI|March 17, 2017
Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV TransmissionQihua Fan, Cody S Nelson, Kristy M Bialas, et al.
Journal of Virology|September 8, 2021
A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>Kevin Chiem, Desarey Morales Vasquez, Jesus A Silvas, et al.
Plos Pathogens|July 21, 2022
Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibodyMichael S Piepenbrink, Jun-Gyu Park, Ashlesha Deshpande, et al.
The Journal of Infectious Diseases|March 23, 2026
Establishment of a Neonatal Natural Transmission Model for CMV Vaccine DevelopmentTeeba Jihad, Xiaoyuan S Chi, Zhiqing He, et al.
Npj Viruses|November 18, 2024
Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsMichael S Piepenbrink, Ahmed Magdy Khalil, Ana Chang, et al.
Cell Reports. Medicine|March 2, 2021
Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamstersMichael S Piepenbrink, Jun-Gyu Park, Fatai S Oladunni, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsMichael S Piepenbrink, Ahmed Magdy Khalil, Ana Chang, et al.
Journal of Clinical Immunology|February 13, 2014
Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantationDhaarini Murugan, Michael H Albert, Jörg Langemeier, et al.
JCI Insight|July 7, 2017
Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeysCody S Nelson, Diana Vera Cruz, Dollnovan Tran, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Biorxiv : the Preprint Server for Biology|March 16, 2022
Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibodyMichael S Piepenbrink, Jun-Gyu Park, Ashlesha Desphande, et al.
Clinical and Vaccine Immunology : CVI|March 17, 2017
Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV TransmissionQihua Fan, Cody S Nelson, Kristy M Bialas, et al.
Journal of Virology|September 8, 2021
A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>Kevin Chiem, Desarey Morales Vasquez, Jesus A Silvas, et al.
Plos Pathogens|July 21, 2022
Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibodyMichael S Piepenbrink, Jun-Gyu Park, Ashlesha Deshpande, et al.
The Journal of Infectious Diseases|March 23, 2026
Establishment of a Neonatal Natural Transmission Model for CMV Vaccine DevelopmentTeeba Jihad, Xiaoyuan S Chi, Zhiqing He, et al.
Npj Viruses|November 18, 2024
Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsMichael S Piepenbrink, Ahmed Magdy Khalil, Ana Chang, et al.
Cell Reports. Medicine|March 2, 2021
Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamstersMichael S Piepenbrink, Jun-Gyu Park, Fatai S Oladunni, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsMichael S Piepenbrink, Ahmed Magdy Khalil, Ana Chang, et al.
Journal of Clinical Immunology|February 13, 2014
Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantationDhaarini Murugan, Michael H Albert, Jörg Langemeier, et al.
JCI Insight|July 7, 2017
Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeysCody S Nelson, Diana Vera Cruz, Dollnovan Tran, et al.
Pageof 9